Table 1 Multicentre analysis of 47 patients re-irradiated with 10 × 3.5 Gy
From: Re-irradiation for recurrent glioblastoma: a pattern of care analysis
Patient Characteristics | n = 47 |
|---|---|
Male : Female | 35 : 12 |
Age (years), median (range) | 61.5 (23–81) |
Karnofsky performance status, median (range) | 90 (60–100) |
WHO glioma classification 3:4 | 4: 43 |
Combs’ modified prognostic scores b: c:d | 25: 18: 4 |
IDH WT : mutant : unknown | 37 : 6: 4 |
MGMT methylation Y: N: unknown | 24: 15: 8 |
Symptoms Y: N | 30: 17 |
Initial 30–33 × 1.8–2 Gy : 15 × 2.67 Gy : other | 39: 6: 2 |
Median PTV at re-mHSRT (cm3) | 22.0 (0.9–190) |
Re-resection prior to re-mHSRT Y : N | 20 : 27 |
Second line systemic therapy prior to re-mHSRT Y : N | 21 : 26 9 temozolomide 9 bevacizumab 1 bevacizumab/lomustine 1 lomustine 1 experimental agent |
Concomitant systemic treatment with re-mHSRT Y: N | 18 : 29 14 temozolomide 4 bevacizumab 29 none |
Systemic treatment following re-mHSRT Y: N:unknown | 28 : 18: 1 10 becavizumab 9 temozolomide 6 bevacizumab/lomustine 2 lomustine 1 surgery and re-mHSRT |
Radionecrosis (n = 45/47 evaluable) | 4 (8.8%) |
Time to re-mHSRT after first RT (mths) median, range | 23.2 (3.4–224) |
Time to progression after first RT (months) median, range | 23.3 (7.0-224) |
Time to progression after re-mHSRT (n = 36) (months) median, range | 6.6 (0.23–92.5) |
Overall survival from start of re-mHSRT (months) median, range | 8.8 (1.50–92.5) |
Overall survival after first progression (months) median, range | 11.8 (2.30–94) |
Overall survival from first diagnosis (months) | 40.6 (8.6 = 229.7 |